Compare ACU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACU | CHRS |
|---|---|---|
| Founded | 1867 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.7M | 177.7M |
| IPO Year | 1994 | 2014 |
| Metric | ACU | CHRS |
|---|---|---|
| Price | $62.07 | $1.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 46.0K | ★ 1.6M |
| Earning Date | 10-23-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | 1.63 | ★ 472.00 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $196,541,816.00 | N/A |
| Revenue This Year | $14.99 | $44.19 |
| Revenue Next Year | $3.98 | $65.06 |
| P/E Ratio | $42.60 | ★ N/A |
| Revenue Growth | ★ 1.05 | N/A |
| 52 Week Low | $35.50 | $0.97 |
| 52 Week High | $64.87 | $2.62 |
| Indicator | ACU | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.93 | 35.54 |
| Support Level | $59.74 | N/A |
| Resistance Level | $64.03 | $1.53 |
| Average True Range (ATR) | 1.37 | 0.07 |
| MACD | -0.29 | -0.01 |
| Stochastic Oscillator | 22.44 | 18.15 |
Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.